Study: Rivaroxaban improves ACS outcomes

04/22/2013 | TCTMD.com · Healio

Acute coronary syndrome patients who were treated with stents had lower rates of mortality and stent thrombosis on a low-dose regime of rivaroxaban in conjunction with aspirin and clopidogrel, according to the ATLAS ACS 2-TIMI 51 trial involving 15,526 patients. "It is not known whether the observed reduction in stent thrombosis in this study is mediated by a reduction in thrombin generation, which in turn directly mediates stent thrombosis, or alternatively, if the reduction in stent thrombosis is mediated by a reduction in the stimulation of platelet aggregation in so far as thrombin is a potent stimulant of platelets," wrote SCAI fellow Dr. Michael Gibson and colleagues.

View Full Article in:

TCTMD.com · Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC